{"entity":{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","aka":["Cellectar Biosciences, Inc.","Cellectar"],"tldr":"Cellectar is a New Jersey radiopharmaceutical company whose iodine-131 phospholipid drug conjugate iopofosine targets the lipid rafts of cancer cells, with a pivotal trial (CLOVER-WaM) in relapsed Waldenström macroglobulinaemia.","summary":"Cellectar Biosciences, based in Florham Park, New Jersey and listed on Nasdaq, develops phospholipid drug conjugates that exploit the lipid rafts abundant on cancer cell membranes to deliver radioisotopes or cytotoxics. Its lead, iopofosine I-131 (CLR 131), delivers iodine-131 and reported its pivotal CLOVER-WaM results in relapsed Waldenström macroglobulinaemia in 2024; earlier studies covered multiple myeloma and paediatric high-grade glioma. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.cellectar.com"},{"label":"ClinicalTrials.gov: trials led by Cellectar Biosciences","url":"https://clinicaltrials.gov/search?lead=Cellectar%20Biosciences"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["waldenstrom","multiple-myeloma"],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Florham Park, NJ","country":"US","companyType":"radiopharma","website":"https://www.cellectar.com","stage":"public","investors":[],"funding":[]},"route":"/companies/cellectar/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}]}}